Despite great expectations and research efforts, anticancer immunotherapy has not yet become a definitive cure. Perhaps, this is because past reductionist approaches were too simplistic for the patient-specific complex system of co-evolving tumor cells and host immunity. Recent efforts based on a systems-based approach promise improved clinical outcomes engendered by a dynamic modification of personalized therapeutic regimens.
机构:
Bristol Myers Squibb Co, Wallingford, CT 06492 USA
Canc Res Inst, Canc Immunotherapy Consortium, New York, NY USABristol Myers Squibb Co, Wallingford, CT 06492 USA
机构:
Bristol Myers Squibb Co, Wallingford, CT 06492 USA
Canc Res Inst, Canc Immunotherapy Consortium, New York, NY USABristol Myers Squibb Co, Wallingford, CT 06492 USA